AstraZeneca’s (NYSE:AZN) CEO Pascal Soriot has said that the company is still aiming for the Oxford COVID-19 vaccine to be ready by this year-end.
Pascal Soriot told during an an online conference that it is unclear how long the trial will be paused in response to a recent adverse event, but a 2020 approval is still on the cards.
The Company expects to have a set of data to submit before year end. Depending on how quickly regulators review the filing, that could enable AstraZeneca to win approval this year.
Soriot said that the decision to resume the coronavirus vaccine trials rests with a group of independent experts who are working to understand if the volunteer’s condition was coincidental or a result of the vaccine.
AZN suspended late-stage trials of its COVID-19 vaccine this week after an illness in a participant in Britain. The patient was reportedly suffering from symptoms associated with a rare spinal inflammatory disorder called transverse myelitis.
Other COVID-19 players: Moderna (NASDAQ:MRNA), Novavax (NASDAQ:NVAX), Sanofi (NASDAQ:SNY), Merck (NYSE:MRK), BioNTech (NASDAQ:BNTX), J&J (NYSE:JNJ), GlaxoSmithKline (NYSE:GSK), Pfizer (NYSE:PFE).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.